comprehensive -WSS

comprehensive

author：focus 2025-09-29 22:46:47 - browse：11

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

hotspot

WSS

Eliminate the waiting period for sterilization covered by Medicaid

Food as medicine: Medically tailored meals may get standardized

Readout LOUD podcast: mifepristone case, GLP

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca says CAR

Let's speed up science by embracing open access publishing

hotspot

comprehensive

focus

Hepatitis C has a cure — but many Americans still lack access to it

FDA's Pazdur wants cancer trials to range beyond China alone

Duchenne breakthrough therapy leaves behind pioneering families

Cord blood banking comes at a high cost to babies

What does generative AI mean for health care? We asked experts

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Sports medicine is finally prioritizing gender equality

Abortion pill case raises question: who can sue the FDA?

Medical records are filled with copy

How to increase colonoscopy rates? Looks like an AI can help

focus

Cord blood banking comes at a high cost to babies

Ionis drug prevents swelling attacks due to hereditary angioedema

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

States should stop sabotaging methadone treatment reform

Supreme Court mifepristone arguments center on docs' right to sue

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

hotspot

explore

explore

knowledge